Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1986 2
1987 1
1989 1
1990 1
1991 3
1992 2
1993 4
1994 4
1996 2
1997 1
1998 6
1999 11
2000 5
2001 7
2002 6
2003 5
2004 6
2005 5
2006 3
2007 1
2009 1
2010 2
2011 1
2012 2
2013 4
2014 8
2016 3
2017 3
2018 4
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

101 results
Results by year
Filters applied: . Clear all
Page 1
Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
Taverna JA, Hung CN, DeArmond DT, Chen M, Lin CL, Osmulski PA, Gaczynska ME, Wang CM, Lucio ND, Chou CW, Chen CL, Nazarullah A, Lampkin SR, Qiu L, Bearss DJ, Warner S, Whatcott CJ, Mouritsen L, Wade M, Weitman S, Mesa RA, Kirma NB, Chao WT, Huang TH. Taverna JA, et al. Among authors: weitman s. Cancer Res. 2020 Apr 1;80(7):1551-1563. doi: 10.1158/0008-5472.CAN-19-3183. Epub 2020 Jan 28. Cancer Res. 2020. PMID: 31992541 Free PMC article.
Combined venetoclax and alvocidib in acute myeloid leukemia.
Bogenberger J, Whatcott C, Hansen N, Delman D, Shi CX, Kim W, Haws H, Soh K, Lee YS, Peterson P, Siddiqui-Jain A, Weitman S, Stewart K, Bearss D, Mesa R, Warner S, Tibes R. Bogenberger J, et al. Among authors: weitman s. Oncotarget. 2017 Nov 3;8(63):107206-107222. doi: 10.18632/oncotarget.22284. eCollection 2017 Dec 5. Oncotarget. 2017. PMID: 29291023 Free PMC article.
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.
Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D. Kelly KR, et al. Among authors: weitman s. Clin Cancer Res. 2018 Dec 15;24(24):6150-6159. doi: 10.1158/1078-0432.CCR-18-0286. Epub 2018 Aug 6. Clin Cancer Res. 2018. PMID: 30082475 Free PMC article. Clinical Trial.
Predicting success in regulatory approval from Phase I results.
Malik L, Mejia A, Parsons H, Ehler B, Mahalingam D, Brenner A, Sarantopoulos J, Weitman S. Malik L, et al. Among authors: weitman s. Cancer Chemother Pharmacol. 2014 Nov;74(5):1099-103. doi: 10.1007/s00280-014-2596-4. Epub 2014 Sep 23. Cancer Chemother Pharmacol. 2014. PMID: 25245822 Free PMC article.
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Stathis A, Flinn IW, Madan S, Maddocks K, Freedman A, Weitman S, Zucca E, Munteanu MC, Lia Palomba M. Stathis A, et al. Among authors: weitman s. Invest New Drugs. 2018 Oct;36(5):869-876. doi: 10.1007/s10637-018-0570-4. Epub 2018 Feb 17. Invest New Drugs. 2018. PMID: 29453628 Free PMC article. Clinical Trial.
WTAP is a novel oncogenic protein in acute myeloid leukemia.
Bansal H, Yihua Q, Iyer SP, Ganapathy S, Proia DA, Penalva LO, Uren PJ, Suresh U, Carew JS, Karnad AB, Weitman S, Tomlinson GE, Rao MK, Kornblau SM, Bansal S. Bansal H, et al. Among authors: weitman s. Leukemia. 2014 May;28(5):1171-4. doi: 10.1038/leu.2014.16. Epub 2014 Jan 13. Leukemia. 2014. PMID: 24413322 Free PMC article. No abstract available.
101 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page